To read the full story, subscribe or sign in.

Sparta to develop new camptothecin formulations

April 5, 1996

No Comments

BioWorld Science Conferences Cancer

Today's news in brief

BioWorld

BioWorld briefs for Nov. 20, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 20, 2024.

Gray and green glass dollar symbols with arrow pointing up

Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly

BioWorld

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

GLP-1s push into MASH as semaglutide 2.4 mg hits endpoints

BioWorld

Positive findings from a phase III trial of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) is moving Novo Nordisk A/S to expand the...

Upgrade your daily dose of biopharma and medtech news

Sparta to develop new camptothecin formulations